Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Name: Kaimen Rigor review — Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Item: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Rating: 59
Author: Alpha1

Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Özgüroğlu M, Pereira de Santana Gomes AJ, Vianna K, Luo H, Gotto GT, Cheng HH, Kim W, Varela CR, Schaeffer D, Kramer K, Li S, Baron B, Shen F, Mundle SD, McCarthy SA, Olmos D, Chi KN, Rathkopf DE

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.25★ (Weak), 0 critical, 0 high issues for “Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03961-8

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/4509c0a1-f9bb-42cd-ad4d-025fbca0d65f" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/4509c0a1-f9bb-42cd-ad4d-025fbca0d65f/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 0 high issues for “Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

380d9eafa6ce7319442a172f7274076362880b92b5a3dd75672372f93867741c

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Paper source

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
StatisticsStatistic did not reproduce−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Reported statistic does not recompute
highArithmeticrecomputedFull detail
Primary endpoint HR in BRCA subgroup
“hazard ratio = 0.52 (95% confidence interval: 0.37–0.72); P < 0.0001”
Find in source
02Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is radiographic progression-free survival (rPFS), a surrogate for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data showing PARP inhibition at the dose used) nor does it cite validated evidence linking rPFS to a hard clinical outcome such as overall survival in this specific setting. The authors note that rPFS has been used as a regulatory endpoint in other phase 3 trials, but they do not provide validation of the surrogate-to-clinical outcome link for this population.
“To reduce timelines to drug approval, radiographic progression-free survival has been used as a regulatory endpoint for several phase 3 trials in mCSPC (for example, ARCHES (NCT02677896), TALAPRO-3 (NCT04821622) and CAPItello-281 (NCT04493853)).”
Find in source
03Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
42.4% does not match the reported count 147/348
“147 patients (42.4%)”
SafetyFind in source

Findings by category

301ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial. All eight rigor dimensions are adequately addressed, with strong reporting of study design, ethics, statistical methods, and data availability. Minor reporting gaps include lack of explicit CONSORT guideline statement and minor copyedit issues.

Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification component recomputed only a subset of tests; 2 of 8 showed minor rounding differences, which do not affect conclusions.

Numerical inconsistencies

3 findings · worst high

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Reported statistics do not recomputeRecomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 7 tests: 6 consistent, 1 inconsistent; 4 recomputed directly from the reported test statistics, 3 via agent-written checks. 1 printed percentage that does not match its own count.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on PARP inhibitors in prostate cancer, the role of HRR gene alterations, and the rationale for combining PARP inhibition with androgen receptor pathway inhibitors. It acknowledges limitations of prior work, such as resistance to PARP inhibitors and the need for earlier intervention. The hypothesis logically follows from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific premise with extensive prior work and a clear rationale for the study hypothesis.

Evidence

“Loss of BRCA was first shown to sensitize cancers to inhibition of PARP via a process known as synthetic lethality”

Introduction ¶1Find in source

“We therefore aimed to evaluate whether the combination of PARP inhibition and an androgen receptor pathway inhibitor at response to first-line androgen deprivation (castration-sensitive prostate cancer) would be effective.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 2]

“Despite the efficacy ... resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function”

PASSReviewer 2· 95% conf

The paper establishes a strong scientific premise by citing prior work on PARP inhibition, HRR alterations, and the rationale for combining PARP and androgen receptor pathway inhibitors in mCSPC.

Evidence

“Despite the efficacy (improvements in both radiographic progression-free survival and overall survival) reported for PARP inhibitor monotherapy in mCRPC ,, , resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function , .”

Introduction ¶1Find in source

Introduction ¶3Find in source

“The relatively low prevalence of individual gene alterations and the heterogeneity of biological sensitization can make interpretation of single-gene groups within individual trials challenging”

Introduction ¶2Find in source

Randomization was done using permuted block randomization via an interactive web randomization system, with stratification factors specified. The trial was double-blind, and blinding was maintained. A power analysis was provided with specific assumptions. Inclusion/exclusion criteria were pre-specified. Outlier handling is addressed through the pre-specified analysis population and missing-data approach. Controls are inherent in the placebo comparator.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was done using permuted block randomization managed via an interactive web randomization system.”

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting